Drug profile · INN
tenecteplase
METALYSE
tenecteplase (METALYSE) is a tissue-type plasminogen activator exogenous protein. Current US regulatory status: approved.
Drug details — tenecteplase
- US status
- approved
- Class
- Blood and blood forming organs (B01)
- Route
- —
- Patents
- 0
- Programs
- 9
- Data quality
- 0.83
Quick answer
tenecteplase (METALYSE) is a tissue-type plasminogen activator exogenous protein. Current US regulatory status: approved.
Key facts
Mechanism of action
Tissue-type plasminogen activator exogenous protein
Primary target: Tissue-type plasminogen activator
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tenecteplase?
tenecteplase (METALYSE) is a tissue-type plasminogen activator exogenous protein. Current US regulatory status: approved.
What is the brand name for tenecteplase?
METALYSE is a marketed brand name for tenecteplase. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tenecteplase?
tenecteplase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.